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ABSTRACT  
The outcome of patients with anaplastic gliomas varies considerably. Whether a molecular 
classification of anaplastic gliomas based on large scale genomic or epigenomic analyses is 
superior to histopathology for reflecting distinct biological groups, predicting outcomes and 
guiding therapy decisions has yet to be determined. 
Epigenome-wide DNA methylation analysis, using a platform which also allows the detection 
of copy-number aberrations, was performed in a cohort of 228 patients with anaplastic 
gliomas (astrocytomas, oligoastrocytomas and oligodendrogliomas), including 115 patients of 
the NOA-04 trial. We further compared these tumors with a group of 55 glioblastomas. 
Unsupervised clustering of DNA methylation patterns revealed two main groups correlated 
with IDH status: CpG island methylator phenotype (CIMP) positive (77.5%) or negative 
(22.5%). CIMPpos (IDH mutant) tumors showed a further separation based on copy-number 
status of chromosome arms 1p and 19q. CIMPneg (IDH wild type) tumors showed hallmark 
copy-number alterations of glioblastomas, and clustered together with CIMPneg glioblastomas 
without forming separate groups based on WHO grade. Notably, there was no molecular 
evidence for a distinct biological entity representing anaplastic oligoastrocytoma. Tumor 
classification based on CIMP and 1p/19q status was significantly associated with survival, 
allowing a better prediction of outcome than the current histopathological classification: 
Patients with CIMPpos tumors with 1p/19q codeletion (CIMP-codel) had the best prognosis, 
followed by patients with CIMPpos tumors but intact 1p/19q status (CIMP-non-codel). Patients 
with CIMPneg anaplastic gliomas (GBM-like) had the worst prognosis. 
Collectively, our data suggest that anaplastic gliomas can be grouped by IDH and 1p/19q 
status into three molecular groups that show clear links to underlying biology and a 
significant association with clinical outcome in a prospective trial cohort. 
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INTRODUCTION 
Anaplastic gliomas of World Health Organization (WHO) grade III comprise a common 
primary CNS tumor in adults. They are histologically subdivided into anaplastic 
astrocytomas, oligodendrogliomas and mixed oligoastrocytomas according to morphological 
criteria [16]. While this histological classification has prognostic value [28], it is prone to high 
interobserver variation, especially for anaplastic oligoastrocytomas, but also for the 
differentiation between anaplastic glioma and glioblastoma (WHO grade IV) [13]. In recent 
years, large-scale genomic and epigenomic studies have greatly increased our insight into the 
biology of malignant gliomas, identifying key alterations and molecular groups [4, 8, 23, 26] 
which may complement the WHO classification. The discovery of a prognostically favorable 
point mutation in isocitrate dehydrogenase 1 (IDH1) codon 132 [19], resulting in a 
neomorphic enzymatic capacity to produce 2-hydroxyglutrate from α-ketoglutarate, has 
considerably changed the understanding of glioma biology [27]. IDH1 (and less frequently 
IDH2) mutations are rare (~5%) in primary glioblastomas, but are found in the majority of 
secondary glioblastomas as well as diffuse (WHO grade II) and anaplastic gliomas, especially 
in oligodendrogliomas [34]. Patients with IDH mutant glioblastoma have a better prognosis 
than IDH wild type anaplastic astrocytoma patients [9]. The IDH mutation causes epigenetic 
remodeling [25], resulting in a CpG island methylator phenotype (CIMP) [18]. Indeed, 
gliomas across histological groups with an IDH mutation carry similar epigenetic profiles [6]. 
This and other studies [14] suggest that IDH mutant gliomas form a biologically distinct 
molecular group from their wild type counterparts. This notion is supported by the finding 
that methylation of the promoter of O6-methylguanine DNA-methyltransferase (MGMT) is 
merely prognostic in IDH mutant anaplastic gliomas, whereas it is predictive for response to 
alkylating chemotherapy in IDH wild type gliomas [29, 31]. 
Besides IDH, it has been known for some time that patients with tumors harboring 1p/19q 
codeletion have a better prognosis [22]. When two phase III trials reported their long-term 
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follow-up, both demonstrating an overall survival benefit from combined treatment with 
radiotherapy and procarbazine, CCNU and vincristine (PCV) chemotherapy mainly in patients 
with 1p/19q codeleted tumors, the 1p/19q codeletion gained predictive properties [2, 5]. 
Mutations of the homolog of the Drosophila gene capicua (CIC) on chromosome 19q and far-
upstream element binding protein 1 (FUBP1) on 1p have been identified as potential 
mechanisms involved in the biology of 1p/19q codeleted gliomas [3]. Gene expression 
clustering plus IDH1 and 1p/19q status revealed molecular groups with prognostic value 
among oligodendroglial tumors [7]. 
Mutually exclusive mutations affecting telomerase reverse transcriptase (TERT) and alpha-
thalassemia/mental retardation syndrome X-linked (ATRX) have been detected in malignant 
gliomas [11, 21]. Two point mutations in the promoter of TERT (C228 and C250) resulting in 
higher TERT mRNA expression were discovered with high frequency in oligodendrogliomas 
(usually co-occurring with 1p/19q codeletion) and primary glioblastomas. Alternative 
lengthening of telomeres (ALT) is another, telomerase-independent mechanism of telomere 
maintenance. ATRX mutations, usually leading to reduced or absent ATRX protein [15], have 
been linked to ALT [10]. Consequently, loss of ATRX expression predominantly occurs in 
astrocytomas and mixed oligoastrocytomas without 1p/19q codeletion (i.e. TERT wild type 
tumors) and seems to identify a prognostically more favorable molecular group among 
anaplastic astrocytoma patients [32]. 
Genome-wide sequencing data in 284 glioblastoma samples from the TCGA consortium 
showed that roughly 50% harbored at least one, usually mutually exclusive somatic mutation 
in genes functionally linked to chromatin organization, such as IDH1/2, SETD2, EZH2, the 
HDAC family or ATRX [4]. Analysis of genome-wide DNA methylation patterns revealed 
distinct molecular groups of glioblastoma, associated with defined hotspot mutations (IDH 
and H3F3A, respectively) or common genomic aberrations like EGFR amplifications [24].  
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In contrast to glioblastomas, anaplastic gliomas have been analyzed less comprehensively [7, 
17]. Here, the feasibility and prognostic value of a molecular classification of anaplastic 
gliomas based on epigenetic and copy-number analysis is investigated. 
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MATERIALS & METHODS 
Patients and tumor samples 
Primary tumor samples of anaplastic gliomas for DNA methylation analysis (n = 228) were 
collected at the Heidelberg University Hospital (Heidelberg, Germany, n = 113) and from the 
NOA-04 trial (n = 115) [28]. 
 
DNA methylation profiling 
For genome-wide assessment of DNA methylation patterns, tumor samples were subjected to 
microarray analyses at the Genomics and Proteomics Core Facility of the German Cancer 
Research Center (DKFZ) using the Infinium HumanMethylation450 BeadChip (Illumina, San 
Diego, CA).  
The following filtering criteria were applied: Removal of probes targeting the X and Y 
chromosomes (n = 11,551), removal of probes containing a single-nucleotide polymorphism 
(dbSNP132 Common) within five base pairs of and including the targeted CpG site (n = 
24,536), and probes not mapping uniquely to the human reference genome (hg19) allowing 
for one mismatch (n = 9,993). In total, 438,370 probes were kept for analysis. 
 
Statistical analysis of DNA methylation 
For unsupervised hierarchical clustering we selected the 10,000 most variable methylated 
probes that showed highest median absolute deviation (MAD) across beta values. Pairwise 
similarity between cases was calculated using euclidean distance and hierarchical clustering 
was performed using Ward's linkage method. To cluster CpG probes we applied hierarchical 
clustering using 1-centered Pearson correlation as similarity measure and average linkage as 
hierarchical clustering method. 
To predict MGMT methylation using methylation (M-values) of CpG probes "cg12434587" 
and "cg12981137" , we applied the logistic regression model MGMT-STP27 [1]. 
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Detection of TERT promoter and ATRX aberrations 
Data for TERT promoter hotspot mutations and for loss of ATRX expression (using 
immunohistochemistry (IHC)) in this patient cohort have been reported before [12, 32]. 
 
Data repository 
Data are accessible at GEO (http://www.ncbi.nlm.nih.gov/geo/), accession number 
GSE58218. Additional methylation data of 55 adult glioblastoma samples used for 
comparison with anaplastic gliomas and six non-neoplastic brain tissue samples used as 
reference to generate copy-number variation plots are publicly available at GEO under the 
accession number GSE36278. 
 
Statistical analysis of clinical and molecular data 
Kaplan-Meier estimator, log rank test and multivariate Cox regression analyses were used to 
assess survival differences. Comparisons of binary and categorical patient characteristics 
between molecular groups were performed by the use of a two-sided Fisher’s exact test. 
Continuous variables were compared using ANOVA and post-hoc pairwise comparisons with 
Holm’s multiple testing procedure. Analyses were carried out using Stata IC version 12.1 
(StataCorp LP, College Station, TX, USA) and R version 3.0.2 [20]. 
ANEU-D-14-00273R -9- 
  
RESULTS 
Unsupervised analysis identifies two main clusters of anaplastic gliomas 
Unsupervised clustering methods using genome-wide DNA methylation patterns generated 
from 228 anaplastic gliomas revealed two main clusters, which were closely associated with 
IDH mutation status (Figure 1): In the first cluster, consisting of 177 (77.5%) samples, 
156/160 samples with available mutation status harbored an IDH mutation (94%, IDH status 
was unavailable for 17 samples). Only 1 out of 35 assessable samples (3%) in the second 
cluster (in total 51 tumors, 22.5%) carried an IDH mutation (IDH status was unavailable for 
16 patients). In analogy to similar DNA methylation patterns observed in glioblastoma, we 
thus refer to the first (hypermethylated) cluster as CIMPpos and to the second cluster as 
CIMPneg (Supplementary Figure 1). Patients with CIMPpos tumors had significantly longer 
overall survival than patients with a CIMPneg tumor (log rank p < 0.001; Supplementary 
Figure 2). Anaplastic astrocytomas were more frequently CIMPneg (34/93, 36.5%) than 
oligodendrogliomas (10/71, 14%) or oligoastrocytomas (7/64, 11%; Fisher’s exact test p < 
0.001, Table 1). 
The effect of IDH mutation on the methylome is so pronounced that identification of further 
molecular groups beyond CIMPpos and CIMPneg is challenging when assessing all samples 
together. We therefore performed an additional analyses using copy-number and methylation 
data in order to investigate potential substructures within these two clusters, and also included 
previously published glioblastomas with known CIMP status [24]. 
 
CIMPpos tumors are subtyped by 1p/19q status 
Unsupervised hierarchical clustering of the 177 CIMPpos anaplastic gliomas and 14 CIMPpos / 
IDH mutant glioblastomas showed a clear separation of samples into two main clusters 
(Figure 2). Copy-number analysis revealed that this separation is based on 1p/19q status, as 
79/82 samples (96%) in one cluster had 1p/19q codeletion as opposed to 8/109 (7%) in the 
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other cluster (Fisher’s exact test, p < 0.001). As expected from the distribution of 1p/19q 
codeletion in anaplastic gliomas, the group with 1p/19q codeletion was significantly enriched 
for oligodendrogliomas and oligoastrocytomas, as was the group with intact 1p/19q status for 
astrocytomas (Table 1). We therefore termed these molecular groups CIMP-codel and CIMP-
non-codel, respectively. There was no further subtyping based on histology, e.g. a split 
between astrocytomas and oligoastrocytomas in the CIMP-non-codel cluster. None of the 14 
CIMPpos glioblastomas displayed a 1p/19q codeletion and all clustered with the CIMP-non-
codel tumors without forming a separate molecular group. Furthermore, characteristic 
glioblastoma copy-number alterations (EGFR amplification, gain of chromosome 7 and loss 
of chromosome 10) were evenly rare in both CIMPpos molecular groups. Homozygous 
CDKN2A deletion occurred in 13/109 CIMP-non-codel tumors (two glioblastomas, 11 
anaplastic gliomas) and in no CIMP-codel tumor. However, the low numbers precluded 
further statistical analysis of survival differences in the above mentioned smaller groups. 
The biological differences between CIMP-non-codel and CIMP-codel tumors are further 
evidenced by the distribution of TERT promoter mutations and ATRX expression in the two 
molecular groups: TERT promoter mutations (C228 and C250) were detected in 57/65 CIMP-
codel tumors (88%), but only in 7/80 in the CIMP-non-codel group (9%, notably, 6 of these 
had 1p/19q codeletion). Conversely, loss of ATRX expression determined by 
immunohistochemistry was common in the CIMP-non-codel group, where 32/40 tumors 
(80%) had lost ATRX expression as opposed to the CIMP-codel group, where only 1/34 
tumors with available ATRX status showed this feature. Of note, no tumor (of 86 samples 
being analyzed both for TERT and ATRX status) displayed both, an ATRX loss and a TERT 
promoter mutation, consistent with these two pathways of telomere lengthening being 
mutually exclusive. 
Interestingly, of the eight tumors with 1p/19q codeletion that were found in the CIMP-non-
codel group by cluster analysis, seven clustered tightly together and had TERT mutations. 
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These tumors stably clustered in the CIMP-non-codel group even when using different 
similarity measures and linkage methods for the hierarchical clustering, indicating that these 
tumors, even while carrying 1p/19q codeletion, have a different methylation profile than the 
majority of the 1p/19q codeleted tumors. By histology, 6/7 of these tumors were diagnosed as 
anaplastic oligodendroglioma.  
Assessment of MGMT promoter methylation using the MGMT-STP27 algorithm [1] revealed 
a high frequency of MGMT promoter methylation in CIMPpos tumors: Of 191 tumors, only 
nine tumors (5%) were predicted to have an unmethylated MGMT promoter. These nine 
samples (eight anaplastic gliomas, one glioblastoma) all belonged to the CIMP-non-codel 
group, while all 82 tumors in the CIMP-codel group were scored as MGMT methylated. 
Importantly though, as the MGMT-STP27 was trained on glioblastoma DNA samples from 
fresh frozen tissue its ability to correctly predict the MGMT status of DNA samples coming 
from FFPE material might be limited (see Supplementary Discussion). 
 
CIMPneg anaplastic gliomas share copy-number aberrations and methylation profiles 
with IDH wild type glioblastomas 
As with the CIMPpos tumors, we grouped the 51 CIMPneg anaplastic gliomas with 41 
glioblastomas with known copy-number and methylation profiles from the study of Sturm et 
al. [24]. Unsupervised clustering did not separate anaplastic gliomas and glioblastomas into 
distinct clusters, with tumors of both WHO grades largely mixing (Figure 3). Subsets of 
CIMPneg anaplastic gliomas clustered together with glioblastomas of each of the 
mesenchymal, RTK I and RTK II groups, respectively. The seeming interposition of the RTK 
I samples in between RTK II samples is most likely caused by different normal cell amounts 
and/or hybridization quality and not a real biological difference between the two RTK II 
clusters. This biological similarity of CIMPneg anaplastic gliomas and glioblastomas based on 
methylation data is also reflected in the copy-number profiles: hallmark glioblastoma 
ANEU-D-14-00273R -12- 
  
alterations were found at similar frequency in anaplastic gliomas and glioblastomas (Fisher’s 
exact test, p > 0.1 for each comparison; Figure 3). Furthermore, copy-number aberrations 
showed typical patterns, for example with EGFR amplifications and CDKN2A deletions 
occurring mostly in RTK II glioblastomas as well as the anaplastic gliomas clustering with 
them. MGMT promoter methylation was also found at similar frequency in both WHO grades: 
23/51 anaplastic gliomas (45%) and 18/41 glioblastomas (44%) were predicted to have a 
methylated MGMT promoter according to the MGMT-STP27 algorithm. In CIMPneg samples 
from NOA-04 (n = 24), MGMT status clearly was associated with differences in progression-
free survival in the chemotherapy arm, while no such obvious effect was seen in the 
radiotherapy arm (Supplementary Figure 3). However, the small number of samples in each 
subgroup precluded further statistical analysis. 
 
Integrated molecular classification is significantly associated with survival 
Taken together, these data suggest that anaplastic gliomas can be robustly divided into three 
main molecular groups based on DNA methylation and copy-number data and independent of 
histology: CIMPneg tumors, which molecularly resemble glioblastomas, CIMP-non-codel 
tumors with intact 1p/19q and CIMP-codel tumors with 1p/19q codeletion (Figure 5). 
Our series of anaplastic gliomas contained 115 samples from the biomarker cohort of the 
NOA-04 trial, which investigated the optimal sequence of radio- and chemotherapy in newly-
diagnosed anaplastic gliomas [28]. Baseline patient characteristics of these 115 samples 
closely resembled those of the entire NOA-04 trial cohort (Supplementary Table 1), except 
for an enrichment of patients with tumor resection as opposed to biopsy due to the tissue 
requirements for DNA methylation analyses. As observed in the entire NOA-04 cohort, both 
treatment sequences performed very similar (log rank test, p = 0.94). 
Of the 115 samples, 24 were CIMPneg, 48 CIMP-non-codel and 43 CIMP-codel. Time to 
treatment failure (TTF), the primary endpoint of NOA-04, showed a clear separation of 
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patients based on molecular classification (Figure 4a): CIMP-codel tumors had the best 
prognosis (median TTF not reached [95% CI 1840 days – not reached]), followed by CIMP-
non-codel tumors (median TTF 1691 days [95% CI 793 – 2315 days]), while CIMPneg tumors 
had the shortest median TTF (496 days [95% CI 326 – 1071 days]). This was also true for 
overall survival (Figure 4b). As opposed to reference histology (Figure 4c,d), this led to a 
clearer separation of prognostic subgroups. Consequently, in a multivariate Cox regression 
model including molecular classification, reference histology and age, only molecular 
classification and age, but not reference histology, were significantly associated with outcome 
(Table 2). To account for potential collinearity between molecular classification and 
reference histology, we analyzed the prediction error curves for Cox models based on 
reference histology or molecular classification only or including both. This indicated again a 
better prediction of survival through the molecular classification as opposed to reference 
histology and only a small improvement of prediction when including both reference 
histology and molecular classification (Supplementary Figure 4).   
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DISCUSSION 
Using DNA methylation profiling and copy-number analysis, we identified three principal 
molecular groups of anaplastic gliomas in a cohort of 228 samples: CIMPneg tumors, which 
resemble glioblastomas, CIMP-codel tumors with 1p/19q codeletion as a hallmark genomic 
alteration and CIMP-non-codel tumors, which lack this copy-number aberration (key 
characteristics are summarized in Table 1); the classification scheme is shown in Figure 5. 
Importantly, this classification not only reflects molecular differences between these groups, 
but also better translates into clinically relevant survival differences when compared with the 
WHO classification as evidenced in the biomarker cohort of the NOA-04 trial (Figure 4, 
Table 2). 
The majority of oligoastrocytomas and oligodendrogliomas [34] belonged to the CIMPpos 
cluster. Based on their epigenome-wide DNA methylation profile, tumors belonging to the 
CIMPpos cluster can be further subdivided by 1p/19q status (also the first split to occur after 
CIMP positive vs. negative when looking at all samples; Figure 1) as suggested before for a 
smaller (n = 46) series of purely oligodendroglial tumors [17]. We termed these clusters 
CIMP-codel (mainly 1p/19q codeleted with oligodendroglial histology) and CIMP-non-codel 
(mainly 1p/19q intact and astrocytic). Notably, the 14 CIMPpos glioblastomas included in this 
analysis all clustered well within the CIMP-non-codel molecular group. On the other hand, 
CIMPneg (and hence IDH wild type) anaplastic gliomas were molecularly indistinguishable 
from CIMPneg glioblastomas: Hallmark glioblastoma copy-number aberrations were found in 
comparable frequency in both tumor grades. Consequently, unsupervised clustering did not 
sort WHO grade III and IV CIMPneg tumors into separate clusters. In contrast, these copy-
number aberrations are rare in CIMPpos tumors (of WHO grade III or IV). Thus, anaplastic 
gliomas and glioblastomas with a given CIMP status are more similar to each other than 
CIMPpos vs. CIMPneg tumors of a certain histology, strongly supporting the notion that IDH 
mutant and IDH wild type tumors are in fact distinct entities [14]. 
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In our cohort, median overall survival was longer in CIMPneg anaplastic gliomas than in 
glioblastomas (Supplementary Figure 5). However, the cohort for this comparison is very 
heterogeneous with respect to treatment and clinical follow-up, including prognostically 
favorable NOA-04 study patients. Longer overall survival for IDH wild type anaplastic 
astrocytomas compared to glioblastomas has been reported in another retrospective series [9]. 
However, in elderly patients with newly diagnosed WHO grade III or IV astrocytomas, which 
are almost always IDH wild type [33], there was no survival difference [30]. Since most 
anaplastic gliomas eventually progress to secondary glioblastomas at recurrence, a survival 
difference may just reflect that CIMPneg anaplastic gliomas are diagnosed in an earlier stage of 
tumor development compared to CIMPneg glioblastoma. Another explanation may be yet to be 
defined groups in the CIMPneg anaplastic gliomas which (i) share a glioblastoma-like clinical 
course or show (ii) a markedly longer survival. For the time being, our findings suggest that 
WHO grading retains a prognostic role within the group of CIMPneg high-grade gliomas. 
Histological classification of anaplastic gliomas, in particular of mixed oligoastrocytomas, has 
considerable interobserver variability [13]. Molecularly, oligoastrocytomas do not form a 
separate biological entity, as they are evenly distributed between the CIMP-codel and CIMP-
non-codel clusters (24 and 33 cases, respectively), while pure oligodendrogliomas and 
astrocytomas were predominantly sorted in the CIMP-codel or CIMP-non-codel cluster, 
respectively (Table 1). Since there is no further subtyping based on histology in either 
CIMPpos cluster, e.g. a split between astrocytomas and oligoastrocytomas in the CIMP-non-
codel cluster, there seems to be no clear biological basis for the diagnosis of an 
oligoastrocytoma. Mean age at diagnosis significantly differed between all three groups 
(Table 1, p < 0.0001, ANOVA). 
With a stringent central histology, NOA-04 demonstrated a clear survival benefit for patients 
with oligodendrogliomas and oligoastrocytomas compared to astrocytomas, which was also 
retained in our cohort of 115 NOA-04 patients (Supplementary Table 2). This cohort is 
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therefore well suited to compare the clinical significance of this molecular classification of 
anaplastic gliomas. In a multivariate Cox regression model, histological assessment did not 
significantly correlate with survival anymore once molecular subtyping was added as a 
covariate, pointing to a diagnostic superiority of molecular subtyping. 
In the long-term follow-up analysis of two large randomized phase III trials, 1p/19q 
codeletion was concordantly shown to predict benefit from radio-chemotherapy [2, 5]. 
However, in both trials several patients with 1p/19q codeletion did not benefit from this 
intensified treatment. In our classification, while 1p/19 status is clearly the defining feature 
for the two molecular groups, 8 out of 95 tumors in the CIMP-non-codel group carried 1p/19q 
codeletion (and TERT mutation). Whether these tumors represent a distinct group is currently 
unclear. An influence of other factors on the DNA methylation profile, such as infiltrating 
normal (reactive) astrocytes can also not be excluded. Based on this observation, however, it 
seems possible that these might be the rare 1p/19q codeleted tumors not benefitting from 
intensified treatment. This hypothesis could be tested in either RTOG-9402 or EORTC-
26951. Furthermore, both trials were designed to include only oligodendroglial tumors, but no 
astrocytomas, although reference histology revealed a relevant proportion of grade II gliomas, 
anaplastic astrocytoma and even glioblastoma [13]. While 1p/19q codeletion occurs only 
infrequently in astrocytomas (three out of 93 anaplastic astrocytomas belonged to the CIMP-
codel group), our observation that anaplastic astrocytoma with 1p/19q codeletion molecularly 
resemble codeleted oligodendroglial tumors supports the notion that this subset should also be 
treated with combined radio-chemotherapy at initial diagnosis.  
In summary, we demonstrate a classification of anaplastic gliomas based on (epi)genome-
wide DNA methylation and copy-number profiles, where tumors can be divided into CIMPpos 
tumors with or without 1p/19q loss, and CIMPneg tumors which closely resemble 
glioblastomas (and may in fact be true glioblastomas biologically, but diagnosed at an earlier 
stage of tumor development, for example). This information, together with MGMT status, can 
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be readily obtained from one platform (450k DNA methylation array), suggesting a possible 
simplification of routine diagnostic testing for this set of tumors. This biological classification 
is also significantly associated with outcome: patients with CIMP-codel tumors have the best 
prognosis, followed by those with CIMP-non-codel tumors and lastly CIMPneg tumors. 
Defining such groups will allow for a clearer understanding of their pathophysiological 
drivers, enabling a more rational search for therapeutic targets. The presented molecular 
classification has the potential to greatly complement the standard histological WHO 
classification by providing a biologically meaningful and clinically relevant stratification 
algorithm, and warrants further examination in future clinical trials. 
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FIGURE LEGENDS 
Figure 1. DNA methylation profiling separates anaplastic gliomas into two main clusters 
based on IDH status. Heatmap of DNA methylation levels in 228 anaplastic gliomas. Each 
row represents a probe and each column a sample. The level of DNA methylation (beta-value) 
is represented with a color scale as depicted. For each sample, IDH mutation and 1p/19q 
copy-number status as well as histology are indicated. 
Figure 2. CIMPpos anaplastic gliomas form two separate molecular subypes closely 
associated with 1p/19q status. DNA methylation heatmap showing the result of an 
unsupervised clustering of 177 CIMPpos anaplastic gliomas and 14 CIMPpos glioblastomas. 
Below, IDH, 1p/19q, TERT, ATRX and MGMT promoter methylation status and histology are 
given. 
Figure 3. Unsupervised clustering analysis of DNA methylation and copy-number 
profiles of CIMPneg anaplastic gliomas (n = 51) and CIMPneg glioblastomas (n = 41) 
reveals a close biological similarity. For each sample, IDH mutation status, copy-number 
aberrations, MGMT promoter methylation status and WHO grade are given. Additionally, 
cluster membership within the six glioblastoma clusters defined by Sturm et al. are given. 
Figure 4. Molecular classification of anaplastic gliomas is a better prognosticator than 
the WHO classification. Kaplan-Meier plots for time to treatment failure (a, c) and overall 
survival (b, d) for the 115 NOA-04 trial samples according to molecular classification (a, b) or 
reference histology (c, d) are shown. 
Figure 5. Summary of the proposed molecular classification. CNVs, copy-number 
variations. 
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TABLES 
Table 1: Key characteristics of molecular groups 
 CIMP-non-codel 
(1p/19q intact) 
CIMP-codel  
(1p/19q codeleted) 
CIMPneg 
(IDH wild type) 
Histology 
  Astrocytoma 
  Oligodendroglioma 
  Oligoastrocytoma 
  Glioblastoma 
 
56 (51%) 
15 (14%) 
24 (22%) 
14 (13%) 
 
3 (4%) 
46 (56%) 
33 (40%) 
0 
 
34 (37%) 
10 (11%) 
7 (7%) 
41 (45%) 
Mean age (years), 
(95%CI) 
38.7 
(36.6 – 40.7) 
45.7 
(43.4 – 48.1) 
49.3 
(46.9 – 51.8) 
IDH 
  Mutated 
  Wild type 
  Not available 
 
97 (96%) 
4 (4%) 
8 
 
73 (100%) 
0 
9 
 
1 (1.5%) 
75 (98.5%) 
16 
1p/19q 
  Codeleted 
  Intact 
 
8 (7%) 
101 (93%) 
 
79 (96%) 
3 (4%) 
 
0 
92 (100%) 
TERT promoter 
  Mutated 
  Wild type 
  Not available 
 
7 (9%) 
73 (91%) 
29 
 
57 (88%) 
8 (12%) 
17 
 
21 (49%) 
22 (51%) 
49 
ATRX 
  Lost 
  Expressed 
 
32 (80%) 
8 (20%) 
 
1 (3%) 
33 (97%) 
 
2 (10%) 
20 (90%) 
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  Not available 69 48 70 
MGMT 
  Methylated 
  Unmethylated 
 
100 (92%) 
9 (8%) 
 
82 (100%) 
0 
 
41 (45%) 
51 (55%) 
EGFR amplification 
  Yes 
  No 
 
2 (2%) 
107 (98%) 
 
1 (1.5%) 
81 (98.5%) 
 
45 (59%) 
47 (51%) 
CDKN2A deletion 
  Yes 
  No 
 
13 (12%) 
96 (88%) 
 
0 
82 (100%) 
 
51 (55.5%) 
41 (44.5%) 
Chr. 7 gain 
  Yes 
  No 
 
3 (2.5%) 
106 (97.5%) 
 
2 (2.5%) 
80 (97.5%) 
 
67 (73.5%) 
24 (26.5%) 
Chr. 10 loss 
  Yes 
  No 
 
1 (1%) 
108 (99%) 
 
0 
82 (100%) 
 
77 (83%) 
15 (17%) 
  
 
Table 2: Multivariate Cox PH regression analysis for TTF in the NOA-04 cohort 
Variable HR 95% CI p 
AO vs. AA 1.76 0.72 – 4.12 0.211 
AA vs. AOA 1.85 0.9 – 3.84 0.093 
CIMP-non-codel vs. 
CIMP-codel 
5.27 2.0 – 13.9 0.001 
CIMPneg vs. 
CIMP-codel 
12.54 5.02 – 31.32 < 0.001 
Age, per year increase 1.05 1.02 – 1.07 0.001 
AA, anaplastic astrocytoma; AO, anaplastic oligodendrogliomas; AOA, anaplastic 
oligoastrocytoma 
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Supplementary Methods 
 
Patients and tumor samples 
The NOA-04 trial (NCT00717210) for patients with newly diagnosed anaplastic gliomas 
compared the efficacy and safety of initial radiotherapy, followed by chemotherapy 
(temozolomide or procarbazine, lomustine and vincristine) at progression or occurrence of 
unacceptable toxicity with the inverse sequence in patients with newly diagnosed anaplastic 
gliomas. In this trial, both sequences achieved similar results [9]. Median follow-up time was 
54 months. All patients consented to exploratory molecular analyses performed with study 
data and materials. The original phase III trial was approved by the Ethics Committee (EC) at 
the University of Tuebingen, Germany, and subsequently all local ECs of the participating 
clinical centers. 
All tumors were banked at the time of primary diagnosis between 1994 and 2013 in 
accordance with research ethics board approval from the respective institutes. Informed 
consent was obtained from all patients included in this study. All samples were independently 
reviewed by neuropathologists (T.P. (NOA-04), A.v.D. and A.K.) according to the WHO 
guidelines. The study additionally included data from 55 glioblastoma samples reported 
before [8]. 
 
Preprocessing of the 450k Infinium methylation data 
The raw methylation data collected from different sources was preprocessed together by using 
the function preprocessIllumina of the Bioconductor Software package Minfi [1]. This 
function is an open source implementation of the normalization procedure developed by 
Illumina which is also available in Illumina's GenomeStudio Software. In brief, this procedure 
uses different internal control probes located on the array to perform background subtraction 
and normalization of the two measured intensity channels. 
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Unsupervised clustering of methylation data 
For unsupervised hierarchical clustering we selected the 10,000 most variable methylated 
probes that showed highest median absolute deviation (MAD) across beta values. Pairwise 
similarity between cases was calculated using euclidean distance and hierarchical clustering 
was performed using Ward's linkage method. To cluster CpG probes we applied hierarchical 
clustering using 1-centered Pearson correlation as similarity measure and average linkage as 
hierarchical clustering method. The same procedure was applied to all three data sets. As 
indicated by the volcano plot in Figure 1 of the Supplementary Material, the CIMP status is 
the dominating signal that might overlay other structures in the data, i.e., unknown molecular 
subgroups. Therefore, to select probes not affected by the CIMP signal and reveal such 
underlying subgroups, unspecific variance filtering and clustering was applied in the same 
way as described above to the two subgroups CIMPpos and CIMPneg.  
 
Detection of copy-number aberrations 
Copy-number data were computed from the 450k Infinium methylation array as described 
previously [8]. Low-resolution copy number variations were detected from the 450k Infinium 
methylation array in a custom approach using the sum of both methylated and unmethylated 
signals. Probes found to be highly variant in the six normal cerebellum samples were 
excluded from the analysis according to the following criteria: Removal of probes not within 
the 0.05 and 0.85 quantile of median summed values or over the 0.8 quantile of the median 
absolute deviation. Log-ratios of samples to the median value of control samples were 
calculated, and sample noisiness was determined as the median absolute deviation of adjacent 
probes. Probes were then combined by joining 20 adjacent probes, and resulting genomic 
windows less than 100kb in size were iteratively merged with adjacent windows of smaller 
size. Windows of more than 5Mb were excluded from analysis, resulting in a total of 8,654 
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windows throughout the genome. For each window, the median probe value was calculated 
and shifted to minimize the median absolute deviation from all windows to zero for every 
sample. Segmentation was performed by applying the circular binary algorithm using the 
following settings: min.width=10, nperm=32000, alpha=0.001, undo.splits="sdundo", 
undo.SD=2.2 [7]. The median value of  windows contained in each segment was calculated, 
and classified as homozygous or hemizygous deletion, neutral, gain or high-level 
amplification by the following arbitrary thresholds: -0.96 , -0.24, 0.12 and 0.72. 
The resulting copy-number plots were individually curated for 1p/19q codeletion, EGFR 
amplification, homozygous CDKN2A deletion and copy-number changes affecting 
chromosomes 7 and 10 (examples in Supplementary Figure 6). 
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Supplementary Discussion 
Methylation of the MGMT promoter is a well-established biomarker predicting benefit from 
temozolomide in glioblastomas [5], which has recently been prospectively confirmed in the 
RTOG-0525 trial [4]. In anaplastic gliomas however, the situation is more complex, as the 
prognostic role of MGMT promoter methylation has been shown to be independent of 
treatment in two phase III trials [3, 9]. A recent analysis suggested an interdependence 
between IDH status and MGMT methylation. In IDH wild type tumors, MGMT is predictive 
specifically for benefit from alkylating chemotherapy, while it is prognostic in IDH mutant 
tumors [10]. The molecular concordance between CIMPneg (IDH wild type) anaplastic 
gliomas and glioblastomas, supports the similar relevance of MGMT in IDH wild type 
anaplastic gliomas and glioblastomas (Supplementary Figure 3). In CIMPpos tumors on the 
other hand, the MGMT-STP27 algorithm, a logistic regression model based on the 
methylation in two CpGs in the differentially methylated regions 1 and 2 of MGMT [2], 
indicated a methylated MGMT promoter in 182 of 191 tumors. Of note however, in our 
database at the DKFZ which comprises methylation data of more than 4000 brain tumors 
covering most known entities we observed consistent batch effects between samples coming 
from FFPE and fresh frozen material for specific CpG probes. Probe cg12434587 which is 
one of the two probes involved in the MGMT-STP27 model seems to be affected by this 
batch effect. Our current estimate for the batch effect for probe cg12434587 is a log2 
difference around 2 for the methylated fluorescence channel. Such an effect may result in 
methylation difference of up 0.3 on the beta scale. Therefore, as the MGMT-STP27 was 
trained on GBM samples from fresh frozen material its ability to correctly predict the MGMT 
status of samples coming from FFPE material might be limited. On the other hand, this high 
rate of MGMT promoter methylation has been reported before in IDH mutant gliomas 
[6]. Interestingly, the 9 MGMT unmethylated tumors all belonged to the CIMP-non-codel 
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group, an observation which is further corroborated when considering the results of the 
centrally performed methylation-specific PCR (MSP) in NOA-04: per MSP, 38 / 42 (90%) 
CIMP-codel tumors, but only 24 / 46 (52%) of CIMP-non-codel tumors had a methylated 
MGMT promoter (Fisher’s exact test, p < 0.001). Mulholland et al. suggested that the 
discrepancy between their finding of nearly 100% MGMT promoter methylation and the MSP 
results might be due to low methylation especially in the MSP-forward region, while 
methylation is higher in surrounding CpGs, still leading to reduced gene expression [6]. 
Hence, it seems possible that the prognostic effect seen with MSP might rather reflect a 
separation between CIMP-codel tumors (which are almost always methylated per MSP) and 
some CIMP-non-codel tumors. 
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Supplementary Figure 1. Volcano plot for differentially methylated probes (using median 
difference and Wilcoxon’s rank sum test). Probes with a significantly (p < 0.05) different 
median methylation between both groups after false discovery rate correction are shown in 
red. 
Supplementary Figure 2. Overall survival by CIMP status in anaplastic gliomas. 
Supplementary Figure 3. Progression-free survival by MGMT status and treatment arm 
(radio- vs. chemotherapy) in the CIMPneg NOA-04 samples (n = 24). 
Supplementary Figure 4. Prediction error curves for time to treatment failure in Cox 
regression models including histology only, molecular classification only, or both. 
Supplementary Figure 5. Overall survival by WHO grade in CIMPneg tumors.  
Supplementary Figure 6. Copy-number plots examples for a case with 1p/19q codeletion (a) 
and another case with EGFR amplification, CDKN2A deletion, gain of chromosome 7 and 
loss of chromosome 10 (b). 
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Supplementary Table 1. Baseline patient characteristics of the NOA-04 cohort 
 NOA-04 Biomarker Cohort NOA-04 Trial Cohort 
 RT 
(n = 65) 
PCV / TMZ 
(n = 50) 
RT 
(n = 139) 
PCV / 
TMZ 
(n = 135) 
Median age 
(range), years 
42 
(23 – 74) 
41.5 
(25 – 64) 
44 
(23 – 74) 
42 
(20 – 77) 
Astrocytoma, n 
Oligoastrocytoma, n 
Oligodendroglioma, n 
28 (43%) 
25 (38%) 
12 (19%) 
22 (43%) 
20 (40%) 
8 (17%) 
70 (50%) 
47 (34%) 
22 (16%) 
74 (55%) 
44 (32%) 
17 (13%) 
Resection, n 
Total 
Subtotal 
Biopsy 
 
31 (48%) 
33 (50.5%) 
1 (1.5%) 
 
22 (44%) 
27 (54%) 
1 (2%) 
 
53 (38%) 
61 (44%) 
25 (18%) 
 
47 (35%) 
57 (42%) 
31 (23%) 
1p/19q co-deletion, n 
Yes 
No 
Information missing 
 
27 (46%) 
31 (54%) 
7 
 
19 (46%) 
22 (54%) 
9 
 
41 (43%) 
54 (57%) 
44 
 
33 (38%) 
53 (62%) 
49 
MGMT promoter, n 
Methylated 
Unmethylated 
Information missing 
 
37 (60%) 
24 (40%) 
4 
 
33 (70%) 
14 (30%) 
3 
 
59 (57%) 
44 (43%) 
36 
 
64 (64%) 
35 (36%) 
36 
IDH mutation, n 
Yes 
 
48 (78%) 
 
35 (74%) 
 
65 (66%) 
 
68 (70%) 
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No 
Information missing 
13 (22%) 
4 
12 (26%) 
3 
33 (34%) 
41 
29 (30%) 
38 
RT, radiotherapy; PCV, procarbazine, CCNU & vincristine; TMZ, temozolomide 
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Supplementary Table 2. Cox regression for TTF by reference histology in NOA-04 
Variable HR 95% CI p 
AO vs. AA 0.64 0.29 – 1.38 0.257 
AOA vs. AA 0.39 0.2 – 0.77 0.006 
AA, anaplastic astrocytoma; AO, anaplastic oligodendrogliomas; AOA, anaplastic 
oligoastrocytoma 
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